Global Rare Disease Drug Market Insights and Forecast to 2026
- BMR3911211
- 154 Pages
- June 2020
- Healthcare
Prior to COVID-19, the market for Rare Disease Drug was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Rare Disease Drug is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Rare Disease Drug market.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Rare Disease Drug market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Rare Disease Drug industry.
Global Rare Disease Drug Scope and Segment
Rare Disease Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Rare Disease Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.
The following manufacturers are covered in this report:
Novartis AG
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Sanofi S.A.
Alexion Pharmaceuticals, Inc.
Eli Lilly and Company
Novo Nordisk A/S
AstraZeneca
Eisai Co., Ltd.
Daiichi Sankyo Company Limited
Bayer AG
GlaxoSmithKline
Merck & Co., Inc.
Johnson & Johnson
Biogen, Inc.
Takeda
Amgen, Inc.
Deciphera
Atara Biotherapeutics
ProQR
Rare Disease Drug Breakdown Data by Type
Above 1‰
0.65‰～1‰
Below 0.1‰
Rare Disease Drug Breakdown Data by Application
Hospital Pharmacies
Speciality Pharmacies
Retail pharmacies
Others
Regional and Country-level Analysis
The Rare Disease Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Rare Disease Drug market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of production capacity, price and revenue for the period 2015-2026.
Competitive Landscape and Rare Disease Drug Market Share Analysis
1.1 Rare Disease Drug Product Introduction
1.2 Market Segments
1.3 Key Rare Disease Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Rare Disease Drug Market Size Growth Rate by Type
1.4.2 Above 1‰
1.4.3 0.65‰～1‰
1.4.4 Below 0.1‰
1.5 Market by Application
1.5.1 Global Rare Disease Drug Market Size Growth Rate by Application
1.5.2 Hospital Pharmacies
1.5.3 Speciality Pharmacies
1.5.4 Retail pharmacies
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Rare Disease Drug Market Size, Estimates and Forecasts
2.1.1 Global Rare Disease Drug Revenue 2015-2026
2.1.2 Global Rare Disease Drug Sales 2015-2026
2.2 Global Rare Disease Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Rare Disease Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Rare Disease Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Rare Disease Drug Competitor Landscape by Players
3.1 Rare Disease Drug Sales by Manufacturers
3.1.1 Rare Disease Drug Sales by Manufacturers (2015-2020)
3.1.2 Rare Disease Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Rare Disease Drug Revenue by Manufacturers
3.2.1 Rare Disease Drug Revenue by Manufacturers (2015-2020)
3.2.2 Rare Disease Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Rare Disease Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Rare Disease Drug Revenue in 2019
3.2.5 Global Rare Disease Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Rare Disease Drug Price by Manufacturers
3.4 Rare Disease Drug Manufacturing Base Distribution, Product Types
3.4.1 Rare Disease Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Rare Disease Drug Product Type
3.4.3 Date of International Manufacturers Enter into Rare Disease Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Rare Disease Drug Market Size by Type (2015-2020)
4.1.1 Global Rare Disease Drug Sales by Type (2015-2020)
4.1.2 Global Rare Disease Drug Revenue by Type (2015-2020)
4.1.3 Rare Disease Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Rare Disease Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Rare Disease Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Rare Disease Drug Revenue Forecast by Type (2021-2026)
4.2.3 Rare Disease Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Rare Disease Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Rare Disease Drug Market Size by Application (2015-2020)
5.1.1 Global Rare Disease Drug Sales by Application (2015-2020)
5.1.2 Global Rare Disease Drug Revenue by Application (2015-2020)
5.1.3 Rare Disease Drug Price by Application (2015-2020)
5.2 Rare Disease Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Rare Disease Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Rare Disease Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Rare Disease Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Rare Disease Drug by Country
6.1.1 North America Rare Disease Drug Sales by Country
6.1.2 North America Rare Disease Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Rare Disease Drug Market Facts & Figures by Type
6.3 North America Rare Disease Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Rare Disease Drug by Country
7.1.1 Europe Rare Disease Drug Sales by Country
7.1.2 Europe Rare Disease Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Rare Disease Drug Market Facts & Figures by Type
7.3 Europe Rare Disease Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Rare Disease Drug by Region
8.1.1 Asia Pacific Rare Disease Drug Sales by Region
8.1.2 Asia Pacific Rare Disease Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Rare Disease Drug Market Facts & Figures by Type
8.3 Asia Pacific Rare Disease Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Rare Disease Drug by Country
9.1.1 Latin America Rare Disease Drug Sales by Country
9.1.2 Latin America Rare Disease Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Rare Disease Drug Market Facts & Figures by Type
9.3 Central & South America Rare Disease Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Rare Disease Drug by Country
10.1.1 Middle East and Africa Rare Disease Drug Sales by Country
10.1.2 Middle East and Africa Rare Disease Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Rare Disease Drug Market Facts & Figures by Type
10.3 Middle East and Africa Rare Disease Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Rare Disease Drug Products Offered
11.1.5 Novartis AG Related Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Corporation Information
11.2.2 Bristol-Myers Squibb Company Description and Business Overview
11.2.3 Bristol-Myers Squibb Company Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bristol-Myers Squibb Company Rare Disease Drug Products Offered
11.2.5 Bristol-Myers Squibb Company Related Developments
11.3 Celgene Corporation
11.3.1 Celgene Corporation Corporation Information
11.3.2 Celgene Corporation Description and Business Overview
11.3.3 Celgene Corporation Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Celgene Corporation Rare Disease Drug Products Offered
11.3.5 Celgene Corporation Related Developments
11.4 F. Hoffmann-La Roche Ltd.
11.4.1 F. Hoffmann-La Roche Ltd. Corporation Information
11.4.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
11.4.3 F. Hoffmann-La Roche Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 F. Hoffmann-La Roche Ltd. Rare Disease Drug Products Offered
11.4.5 F. Hoffmann-La Roche Ltd. Related Developments
11.5 Pfizer, Inc.
11.5.1 Pfizer, Inc. Corporation Information
11.5.2 Pfizer, Inc. Description and Business Overview
11.5.3 Pfizer, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Pfizer, Inc. Rare Disease Drug Products Offered
11.5.5 Pfizer, Inc. Related Developments
11.6 Sanofi S.A.
11.6.1 Sanofi S.A. Corporation Information
11.6.2 Sanofi S.A. Description and Business Overview
11.6.3 Sanofi S.A. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Sanofi S.A. Rare Disease Drug Products Offered
11.6.5 Sanofi S.A. Related Developments
11.7 Alexion Pharmaceuticals, Inc.
11.7.1 Alexion Pharmaceuticals, Inc. Corporation Information
11.7.2 Alexion Pharmaceuticals, Inc. Description and Business Overview
11.7.3 Alexion Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Alexion Pharmaceuticals, Inc. Rare Disease Drug Products Offered
11.7.5 Alexion Pharmaceuticals, Inc. Related Developments
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Corporation Information
11.8.2 Eli Lilly and Company Description and Business Overview
11.8.3 Eli Lilly and Company Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Eli Lilly and Company Rare Disease Drug Products Offered
11.8.5 Eli Lilly and Company Related Developments
11.9 Novo Nordisk A/S
11.9.1 Novo Nordisk A/S Corporation Information
11.9.2 Novo Nordisk A/S Description and Business Overview
11.9.3 Novo Nordisk A/S Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Novo Nordisk A/S Rare Disease Drug Products Offered
11.9.5 Novo Nordisk A/S Related Developments
11.10 AstraZeneca
11.10.1 AstraZeneca Corporation Information
11.10.2 AstraZeneca Description and Business Overview
11.10.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.10.4 AstraZeneca Rare Disease Drug Products Offered
11.10.5 AstraZeneca Related Developments
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Rare Disease Drug Products Offered
11.1.5 Novartis AG Related Developments
11.12 Daiichi Sankyo Company Limited
11.12.1 Daiichi Sankyo Company Limited Corporation Information
11.12.2 Daiichi Sankyo Company Limited Description and Business Overview
11.12.3 Daiichi Sankyo Company Limited Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Daiichi Sankyo Company Limited Products Offered
11.12.5 Daiichi Sankyo Company Limited Related Developments
11.13 Bayer AG
11.13.1 Bayer AG Corporation Information
11.13.2 Bayer AG Description and Business Overview
11.13.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Bayer AG Products Offered
11.13.5 Bayer AG Related Developments
11.14 GlaxoSmithKline
11.14.1 GlaxoSmithKline Corporation Information
11.14.2 GlaxoSmithKline Description and Business Overview
11.14.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.14.4 GlaxoSmithKline Products Offered
11.14.5 GlaxoSmithKline Related Developments
11.15 Merck & Co., Inc.
11.15.1 Merck & Co., Inc. Corporation Information
11.15.2 Merck & Co., Inc. Description and Business Overview
11.15.3 Merck & Co., Inc. Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Merck & Co., Inc. Products Offered
11.15.5 Merck & Co., Inc. Related Developments
11.16 Johnson & Johnson
11.16.1 Johnson & Johnson Corporation Information
11.16.2 Johnson & Johnson Description and Business Overview
11.16.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Johnson & Johnson Products Offered
11.16.5 Johnson & Johnson Related Developments
11.17 Biogen, Inc.
11.17.1 Biogen, Inc. Corporation Information
11.17.2 Biogen, Inc. Description and Business Overview
11.17.3 Biogen, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.17.4 Biogen, Inc. Products Offered
11.17.5 Biogen, Inc. Related Developments
11.18 Takeda
11.18.1 Takeda Corporation Information
11.18.2 Takeda Description and Business Overview
11.18.3 Takeda Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Takeda Products Offered
11.18.5 Takeda Related Developments
11.19 Amgen, Inc.
11.19.1 Amgen, Inc. Corporation Information
11.19.2 Amgen, Inc. Description and Business Overview
11.19.3 Amgen, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.19.4 Amgen, Inc. Products Offered
11.19.5 Amgen, Inc. Related Developments
11.20 Deciphera
11.20.1 Deciphera Corporation Information
11.20.2 Deciphera Description and Business Overview
11.20.3 Deciphera Sales, Revenue and Gross Margin (2015-2020)
11.20.4 Deciphera Products Offered
11.20.5 Deciphera Related Developments
11.21 Atara Biotherapeutics
11.21.1 Atara Biotherapeutics Corporation Information
11.21.2 Atara Biotherapeutics Description and Business Overview
11.21.3 Atara Biotherapeutics Sales, Revenue and Gross Margin (2015-2020)
11.21.4 Atara Biotherapeutics Products Offered
11.21.5 Atara Biotherapeutics Related Developments
11.22 ProQR
11.22.1 ProQR Corporation Information
11.22.2 ProQR Description and Business Overview
11.22.3 ProQR Sales, Revenue and Gross Margin (2015-2020)
11.22.4 ProQR Products Offered
11.22.5 ProQR Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Rare Disease Drug Market Estimates and Projections by Region
12.1.1 Global Rare Disease Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Rare Disease Drug Revenue Forecast by Regions 2021-2026
12.2 North America Rare Disease Drug Market Size Forecast (2021-2026)
12.2.1 North America: Rare Disease Drug Sales Forecast (2021-2026)
12.2.2 North America: Rare Disease Drug Revenue Forecast (2021-2026)
12.2.3 North America: Rare Disease Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Rare Disease Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Rare Disease Drug Sales Forecast (2021-2026)
12.3.2 Europe: Rare Disease Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Rare Disease Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Rare Disease Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Rare Disease Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Rare Disease Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Rare Disease Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Rare Disease Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Rare Disease Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Rare Disease Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Rare Disease Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Rare Disease Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Rare Disease Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Rare Disease Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Rare Disease Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Rare Disease Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Rare Disease Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Licenses Type
USD 3,900 Single License
USD 7,800 Enterprise License
BUY NOW Add to Cart
Why QYR
Fastest report delivery service
More than 10 years of vast experience
Operational for 24 * 7 & 365 days
In-depth and comprehensive analysis
Excellent after sales support
Owns large database
Need Help ?
Email Us FAQ
Global Rare Disease Drug market
Table 1. Rare Disease Drug Market Segments
Table 2. Ranking of Global Top Rare Disease Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Rare Disease Drug Market Size Growth Rate by Type 2020-2026 (K Doses) & (US$ Million)
Table 4. Major Manufacturers of Above 1‰
Table 5. Major Manufacturers of 0.65‰～1‰
Table 6. Major Manufacturers of Below 0.1‰
Table 7. Global Rare Disease Drug Market Size Growth Rate by Application 2020-2026 (K Doses)
Table 8. Global Rare Disease Drug Market Size by Region (K Doses) & (US$ Million): 2020 VS 2026
Table 9. Global Rare Disease Drug Sales by Regions 2015-2020 (K Doses)
Table 10. Global Rare Disease Drug Sales Market Share by Regions (2015-2020)
Table 11. Global Rare Disease Drug Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Rare Disease Drug Sales by Manufacturers (2015-2020) (K Doses)
Table 13. Global Rare Disease Drug Sales Share by Manufacturers (2015-2020)
Table 14. Global Rare Disease Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global Rare Disease Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Rare Disease Drug as of 2019)
Table 16. Rare Disease Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. Rare Disease Drug Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers Rare Disease Drug Price (2015-2020) (USD/Dose)
Table 19. Rare Disease Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Rare Disease Drug Product Type
Table 21. Date of International Manufacturers Enter into Rare Disease Drug Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global Rare Disease Drug Sales by Type (2015-2020) (K Doses)
Table 24. Global Rare Disease Drug Sales Share by Type (2015-2020)
Table 25. Global Rare Disease Drug Revenue by Type (2015-2020) (US$ Million)
Table 26. Global Rare Disease Drug Revenue Share by Type (2015-2020)
Table 27. Rare Disease Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Dose)
Table 28. Global Rare Disease Drug Sales by Application (2015-2020) (K Doses)
Table 29. Global Rare Disease Drug Sales Share by Application (2015-2020)
Table 30. North America Rare Disease Drug Sales by Country (2015-2020) (K Doses)
Table 31. North America Rare Disease Drug Sales Market Share by Country (2015-2020)
Table 32. North America Rare Disease Drug Revenue by Country (2015-2020) (US$ Million)
Table 33. North America Rare Disease Drug Revenue Market Share by Country (2015-2020)
Table 34. North America Rare Disease Drug Sales by Type (2015-2020) (K Doses)
Table 35. North America Rare Disease Drug Sales Market Share by Type (2015-2020)
Table 36. North America Rare Disease Drug Sales by Application (2015-2020) (K Doses)
Table 37. North America Rare Disease Drug Sales Market Share by Application (2015-2020)
Table 38. Europe Rare Disease Drug Sales by Country (2015-2020) (K Doses)
Table 39. Europe Rare Disease Drug Sales Market Share by Country (2015-2020)
Table 40. Europe Rare Disease Drug Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe Rare Disease Drug Revenue Market Share by Country (2015-2020)
Table 42. Europe Rare Disease Drug Sales by Type (2015-2020) (K Doses)
Table 43. Europe Rare Disease Drug Sales Market Share by Type (2015-2020)
Table 44. Europe Rare Disease Drug Sales by Application (2015-2020) (K Doses)
Table 45. Europe Rare Disease Drug Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific Rare Disease Drug Sales by Region (2015-2020) (K Doses)
Table 47. Asia Pacific Rare Disease Drug Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific Rare Disease Drug Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific Rare Disease Drug Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific Rare Disease Drug Sales by Type (2015-2020) (K Doses)
Table 51. Asia Pacific Rare Disease Drug Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific Rare Disease Drug Sales by Application (2015-2020) (K Doses)
Table 53. Asia Pacific Rare Disease Drug Sales Market Share by Application (2015-2020)
Table 54. Latin America Rare Disease Drug Sales by Country (2015-2020) (K Doses)
Table 55. Latin America Rare Disease Drug Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa Rare Disease Drug Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America Rare Disease Drug Revenue Market Share by Country (2015-2020)
Table 58. Latin America Rare Disease Drug Sales by Type (2015-2020) (K Doses)
Table 59. Latin America Rare Disease Drug Sales Market Share by Type (2015-2020)
Table 60. Latin America Rare Disease Drug Sales by Application (2015-2020) (K Doses)
Table 61. Latin America Rare Disease Drug Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa Rare Disease Drug Sales by Country (2015-2020) (K Doses)
Table 63. Middle East and Africa Rare Disease Drug Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa Rare Disease Drug Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa Rare Disease Drug Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa Rare Disease Drug Sales by Type (2015-2020) (K Doses)
Table 67. Middle East and Africa Rare Disease Drug Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa Rare Disease Drug Sales by Application (2015-2020) (K Doses)
Table 69. Middle East and Africa Rare Disease Drug Sales Market Share by Application (2015-2020)
Table 70. Novartis AG Corporation Information
Table 71. Novartis AG Description and Major Businesses
Table 72. Novartis AG Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 73. Novartis AG Product
Table 74. Novartis AG Recent Development
Table 75. Bristol-Myers Squibb Company Corporation Information
Table 76. Bristol-Myers Squibb Company Description and Major Businesses
Table 77. Bristol-Myers Squibb Company Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 78. Bristol-Myers Squibb Company Product
Table 79. Bristol-Myers Squibb Company Recent Development
Table 80. Celgene Corporation Corporation Information
Table 81. Celgene Corporation Description and Major Businesses
Table 82. Celgene Corporation Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 83. Celgene Corporation Product
Table 84. Celgene Corporation Recent Development
Table 85. F. Hoffmann-La Roche Ltd. Corporation Information
Table 86. F. Hoffmann-La Roche Ltd. Description and Major Businesses
Table 87. F. Hoffmann-La Roche Ltd. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 88. F. Hoffmann-La Roche Ltd. Product
Table 89. F. Hoffmann-La Roche Ltd. Recent Development
Table 90. Pfizer, Inc. Corporation Information
Table 91. Pfizer, Inc. Description and Major Businesses
Table 92. Pfizer, Inc. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 93. Pfizer, Inc. Product
Table 94. Pfizer, Inc. Recent Development
Table 95. Sanofi S.A. Corporation Information
Table 96. Sanofi S.A. Description and Major Businesses
Table 97. Sanofi S.A. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 98. Sanofi S.A. Product
Table 99. Sanofi S.A. Recent Development
Table 100. Alexion Pharmaceuticals, Inc. Corporation Information
Table 101. Alexion Pharmaceuticals, Inc. Description and Major Businesses
Table 102. Alexion Pharmaceuticals, Inc. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 103. Alexion Pharmaceuticals, Inc. Product
Table 104. Alexion Pharmaceuticals, Inc. Recent Development
Table 105. Eli Lilly and Company Corporation Information
Table 106. Eli Lilly and Company Description and Major Businesses
Table 107. Eli Lilly and Company Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 108. Eli Lilly and Company Product
Table 109. Eli Lilly and Company Recent Development
Table 110. Novo Nordisk A/S Corporation Information
Table 111. Novo Nordisk A/S Description and Major Businesses
Table 112. Novo Nordisk A/S Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 113. Novo Nordisk A/S Product
Table 114. Novo Nordisk A/S Recent Development
Table 115. AstraZeneca Corporation Information
Table 116. AstraZeneca Description and Major Businesses
Table 117. AstraZeneca Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 118. AstraZeneca Product
Table 119. AstraZeneca Recent Development
Table 120. Eisai Co., Ltd. Corporation Information
Table 121. Eisai Co., Ltd. Description and Major Businesses
Table 122. Eisai Co., Ltd. Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 123. Eisai Co., Ltd. Product
Table 124. Eisai Co., Ltd. Recent Development
Table 125. Daiichi Sankyo Company Limited Corporation Information
Table 126. Daiichi Sankyo Company Limited Description and Major Businesses
Table 127. Daiichi Sankyo Company Limited Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 128. Daiichi Sankyo Company Limited Product
Table 129. Daiichi Sankyo Company Limited Recent Development
Table 130. Bayer AG Corporation Information
Table 131. Bayer AG Description and Major Businesses
Table 132. Bayer AG Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 133. Bayer AG Product
Table 134. Bayer AG Recent Development
Table 135. GlaxoSmithKline Corporation Information
Table 136. GlaxoSmithKline Description and Major Businesses
Table 137. GlaxoSmithKline Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 138. GlaxoSmithKline Product
Table 139. GlaxoSmithKline Recent Development
Table 140. Merck & Co., Inc. Corporation Information
Table 141. Merck & Co., Inc. Description and Major Businesses
Table 142. Merck & Co., Inc. Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 143. Merck & Co., Inc. Product
Table 144. Merck & Co., Inc. Recent Development
Table 145. Johnson & Johnson Corporation Information
Table 146. Johnson & Johnson Description and Major Businesses
Table 147. Johnson & Johnson Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 148. Johnson & Johnson Product
Table 149. Johnson & Johnson Recent Development
Table 150. Biogen, Inc. Corporation Information
Table 151. Biogen, Inc. Description and Major Businesses
Table 152. Biogen, Inc. Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 153. Biogen, Inc. Product
Table 154. Biogen, Inc. Recent Development
Table 155. Takeda Corporation Information
Table 156. Takeda Description and Major Businesses
Table 157. Takeda Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 158. Takeda Product
Table 159. Takeda Recent Development
Table 160. Amgen, Inc. Corporation Information
Table 161. Amgen, Inc. Description and Major Businesses
Table 162. Amgen, Inc. Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 163. Amgen, Inc. Product
Table 164. Amgen, Inc. Recent Development
Table 165. Deciphera Corporation Information
Table 166. Deciphera Description and Major Businesses
Table 167. Deciphera Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 168. Deciphera Product
Table 169. Deciphera Recent Development
Table 170. Atara Biotherapeutics Corporation Information
Table 171. Atara Biotherapeutics Description and Major Businesses
Table 172. Atara Biotherapeutics Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 173. Atara Biotherapeutics Product
Table 174. Atara Biotherapeutics Recent Development
Table 175. ProQR Corporation Information
Table 176. ProQR Description and Major Businesses
Table 177. ProQR Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 178. ProQR Product
Table 179. ProQR Recent Development
Table 180. Global Rare Disease Drug Sales Forecast by Regions (2021-2026) (K Doses)
Table 181. Global Rare Disease Drug Sales Market Share Forecast by Regions (2021-2026)
Table 182. Global Rare Disease Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 183. Global Rare Disease Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 184. North America: Rare Disease Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 185. North America: Rare Disease Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 186. Europe: Rare Disease Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 187. Europe: Rare Disease Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 188. Asia Pacific: Rare Disease Drug Sales Forecast by Region (2021-2026) (K Doses)
Table 189. Asia Pacific: Rare Disease Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 190. Latin America: Rare Disease Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 191. Latin America: Rare Disease Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 192. Middle East and Africa: Rare Disease Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 193. Middle East and Africa: Rare Disease Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 194. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 195. Key Challenges
Table 196. Market Risks
Table 197. Main Points Interviewed from Key Rare Disease Drug Players
Table 198. Rare Disease Drug Customers List
Table 199. Rare Disease Drug Distributors List
Table 200. Research Programs/Design for This Report
Table 201. Key Data Information from Secondary Sources
Table 202. Key Data Information from Primary Sources
List of Figures
Figure 1. Rare Disease Drug Product Picture
Figure 2. Global Rare Disease Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Above 1‰ Product Picture
Figure 4. 0.65‰～1‰ Product Picture
Figure 5. Below 0.1‰ Product Picture
Figure 6. Global Rare Disease Drug Sales Market Share by Application in 2020 & 2026
Figure 7. Hospital Pharmacies
Figure 8. Speciality Pharmacies
Figure 9. Retail pharmacies
Figure 10. Others
Figure 11. Rare Disease Drug Report Years Considered
Figure 12. Global Rare Disease Drug Market Size 2015-2026 (US$ Million)
Figure 13. Global Rare Disease Drug Sales 2015-2026 (K Doses)
Figure 14. Global Rare Disease Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Rare Disease Drug Sales Market Share by Region (2015-2020)
Figure 16. Global Rare Disease Drug Sales Market Share by Region in 2019
Figure 17. Global Rare Disease Drug Revenue Market Share by Region (2015-2020)
Figure 18. Global Rare Disease Drug Revenue Market Share by Region in 2019
Figure 19. Global Rare Disease Drug Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Rare Disease Drug Revenue in 2019
Figure 21. Rare Disease Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Rare Disease Drug Sales Market Share by Type (2015-2020)
Figure 23. Global Rare Disease Drug Sales Market Share by Type in 2019
Figure 24. Global Rare Disease Drug Revenue Market Share by Type (2015-2020)
Figure 25. Global Rare Disease Drug Revenue Market Share by Type in 2019
Figure 26. Global Rare Disease Drug Market Share by Price Range (2015-2020)
Figure 27. Global Rare Disease Drug Sales Market Share by Application (2015-2020)
Figure 28. Global Rare Disease Drug Sales Market Share by Application in 2019
Figure 29. Global Rare Disease Drug Revenue Market Share by Application (2015-2020)
Figure 30. Global Rare Disease Drug Revenue Market Share by Application in 2019
Figure 31. North America Rare Disease Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 32. North America Rare Disease Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Rare Disease Drug Sales Market Share by Country in 2019
Figure 34. North America Rare Disease Drug Revenue Market Share by Country in 2019
Figure 35. U.S. Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 36. U.S. Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 38. Canada Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Rare Disease Drug Market Share by Type in 2019
Figure 40. North America Rare Disease Drug Market Share by Application in 2019
Figure 41. Europe Rare Disease Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 42. Europe Rare Disease Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Rare Disease Drug Sales Market Share by Country in 2019
Figure 44. Europe Rare Disease Drug Revenue Market Share by Country in 2019
Figure 45. Germany Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 46. Germany Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 48. France Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 50. U.K. Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 52. Italy Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 54. Russia Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Rare Disease Drug Market Share by Type in 2019
Figure 56. Europe Rare Disease Drug Market Share by Application in 2019
Figure 57. Asia Pacific Rare Disease Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 58. Asia Pacific Rare Disease Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Rare Disease Drug Sales Market Share by Region in 2019
Figure 60. Asia Pacific Rare Disease Drug Revenue Market Share by Region in 2019
Figure 61. China Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 62. China Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 64. Japan Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 66. South Korea Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 68. India Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 70. Australia Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 72. Taiwan Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 74. Indonesia Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 76. Thailand Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 78. Malaysia Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 80. Philippines Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 82. Vietnam Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Rare Disease Drug Market Share by Type in 2019
Figure 84. Asia Pacific Rare Disease Drug Market Share by Application in 2019
Figure 85. Latin America Rare Disease Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 86. Latin America Rare Disease Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Rare Disease Drug Sales Market Share by Country in 2019
Figure 88. Latin America Rare Disease Drug Revenue Market Share by Country in 2019
Figure 89. Mexico Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 90. Mexico Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 92. Brazil Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 94. Argentina Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Rare Disease Drug Market Share by Type in 2019
Figure 96. Latin America Rare Disease Drug Market Share by Application in 2019
Figure 97. Middle East and Africa Rare Disease Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 98. Middle East and Africa Rare Disease Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Rare Disease Drug Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Rare Disease Drug Revenue Market Share by Country in 2019
Figure 101. Turkey Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 102. Turkey Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 104. Saudi Arabia Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Rare Disease Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 106. U.A.E Rare Disease Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Rare Disease Drug Market Share by Type in 2019
Figure 108. Middle East and Africa Rare Disease Drug Market Share by Application in 2019
Figure 109. North America Rare Disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 110. North America Rare Disease Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Rare Disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 112. Europe Rare Disease Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Rare Disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 114. Asia Pacific Rare Disease Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Rare Disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 116. Latin America Rare Disease Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Rare Disease Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 118. Middle East and Africa Rare Disease Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
Licenses Type
USD 3,900 Single License
USD 7,800 Enterprise License
BUY NOW Add to Cart
Why QYR
Fastest report delivery service
More than 10 years of vast experience
Operational for 24 * 7 & 365 days
In-depth and comprehensive analysis
Excellent after sales support
Owns large database
Need Help ?
Email Us FAQ
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
